CovalentMod Profile Banner
Covalent Modifiers Profile
Covalent Modifiers

@CovalentMod

Followers
5K
Following
66
Media
424
Statuses
843

A feed for the blog https://t.co/pXYAKACULR. Discusses the covalent modification of proteins. Available on bsky and mass std don

Ottawa, Ontario
Joined April 2017
Don't wanna be here? Send us removal request.
@CovalentMod
Covalent Modifiers
3 months
FYI, the code that tweets out notices of new posts stopped working some months ago. If you'd like to continuing following this content, subscribe to the blog feed directly or follow us on bsky.
0
0
1
@CovalentMod
Covalent Modifiers
6 months
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
0
0
6
@CovalentMod
Covalent Modifiers
6 months
Design, synthesis and biological evaluation of the activity-based probes for FGFR covalent inhibitor
0
2
6
@CovalentMod
Covalent Modifiers
6 months
Discovery of a Novel Serine-Targeting Covalent Inhibitor against HCES2A for Treating Drug-induced Diarrhea and Ulcerative Colitis
0
0
6
@CovalentMod
Covalent Modifiers
6 months
Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of the mitophagy regulator USP30
0
0
2
@CovalentMod
Covalent Modifiers
6 months
Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine
0
0
1
@CovalentMod
Covalent Modifiers
6 months
Discovery of Carbodiimide Warheads to Selectively and Covalently Target Aspartic Acid in KRASG12D
0
1
7
@CovalentMod
Covalent Modifiers
6 months
Residue-Selective Inhibitors Discovery via Covalent DNA-Encoded Chemical Libraries with Diverse Warheads
0
0
4
@CovalentMod
Covalent Modifiers
6 months
Glecirasib, a potent and selective covalent KRAS G12C inhibitor exhibiting synergism 2 with cetuximab or SHP2 inhibitor JAB-3312
0
3
6
@HartungIngo
Ingo Hartung
7 months
Clinical update for zoldonrasib - Ras(on)G12D selective covalent inhibitor - dosed at 1200 mg qd po (MTD previously not reached). Generally well tolerated, 89% disease control rate for NSCLC patients, two promising case studies shared, but still very early days. #AACR25 @AACR
0
10
42
@CovalentMod
Covalent Modifiers
7 months
Discovery and Optimization of a Covalent AKR1C3 Inhibitor
0
0
1
@CovalentMod
Covalent Modifiers
7 months
DCAF16-Based Covalent Degradative Handles for the Modular Design of Degraders
0
1
4
@CovalentMod
Covalent Modifiers
7 months
Proteomic Ligandability Maps of Phosphorus(V) Stereoprobes Identify Covalent TLCD1 Inhibitors
0
0
4
@CovalentMod
Covalent Modifiers
7 months
Discovery and Optimization of a Covalent AKR1C3 Inhibitor
0
0
5
@CovalentMod
Covalent Modifiers
7 months
Discovery of RNA-Reactive Small Molecules Guides Design of Electrophilic Modules for RNA-Specific Covalent Binders
0
1
2
@CovalentMod
Covalent Modifiers
7 months
Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria
0
0
2
@CovalentMod
Covalent Modifiers
7 months
Substrate Trapping in Polyketide Synthase Thioesterase Domains: Structural Basis for Macrolactone Formation
0
0
1
@CovalentMod
Covalent Modifiers
7 months
Covalent Modification of Glutamic Acid Inspired by HaloTag Technology
0
0
2
@CovalentMod
Covalent Modifiers
7 months
A predictive model for thiol reactivity of N-heteroaryl α-methylene–γ-lactams—a medicinally relevant covalent reactive group
0
1
6